| Bioactivity | Enalaprilat (MK-422 anhydrous), the active metabolite of the oral prodrug Enalapril, is a potent, competitive and long-acting angiotensin-converting enzyme (ACE) inhibitor, with an IC50 of 1.94 nM. Enalaprilat can be used for the research of hypertension[1][2][3]. |
| Target | IC50: 1.94 nM (ACE) |
| Invitro | Enalaprilat (1 nM-10 μM; 24 h) attenuates the IGF-I induced neonatal rat cardiac fibroblast growth (30% reduction) in a concentration-dependent fashion, with an IC50 of 90 mM[2]. |
| In Vivo | Enalaprilat (0.01%-2.9% in the eyedrop solution) shows significant intraocular pressure (IOP)-lowering effect in rabbits[3]. |
| Name | Enalaprilat |
| CAS | 76420-72-9 |
| Formula | C18H24N2O5 |
| Molar Mass | 348.39 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ceconi C, et, al. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol. 2007 Dec 22;577(1-3):1-6. [2]. Eickels M, et, al. Angiotensin-converting enzyme (ACE) inhibition attenuates insulin-like growth factor-I (IGF-I) induced cardiac fibroblast proliferation. Br J Pharmacol. 2000 Dec;131(8):1592-6. [3]. Loftsson T, et, al. Enalaprilat and enalapril maleate eyedrops lower intraocular pressure in rabbits. Acta Ophthalmol. 2010 May;88(3):337-41. |
Enalaprilat
CAS: 76420-72-9 F: C18H24N2O5 W: 348.39
Enalaprilat (MK-422 anhydrous), the active metabolite of the oral prodrug Enalapril, is a potent, competitive and long-a
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.